Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%.

This report focuses on the key therapy area indications of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The approval of the products Kalydeco and Orkambi, in 2012 and 2014 respectively, gave patients disease-modifying treatment options for CF. Targeted biologics have also emerged such as omalizumab and Nucala for the treatment of asthma.

Overall, 937 products are being actively developed in the respiratory pipeline. The pipelines of asthma, COPD, IPF and CF contain 261, 106, 79 and 131 products, respectively. Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area.

Request a Free sample Report Here @ https://www.jsbmarketresearch.com/sample-request/global-respiratory-drugs-market-to-2023

Scope

• The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?

• Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Reasons to buy

• Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.

• Predict growth in market size, with in-depth market forecasting from 2016 to 2023.

• Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.

Browse a Full Report Here @ https://www.jsbmarketresearch.com/healthcare-medical/global-respiratory-drugs-market-to-2023

Key Marketed Products:

• Advair - GSK

• Symbicort - AstraZeneca/Astellas

• Spiriva - Boehringer Ingelheim

• Xolair - Roche/Novartis

• Ventolin - GSK

• Pulmicort - Astra Zeneca

• Orkambi - Vertex

• About JSB Market Research -

  JSB market research is one of the most significant databases of online market researches and intelligence reports and services. we specialize in providing market research reports for various industries. the online portal for marketing research deals with access to global market data and assists in providing expert.

   

  For Further Information, Kindly Contact:

  JSB Market Research

  Phone: +917710006748

  Website: www.jsbmarketresearch.com

  Email: - enquiry@jsbmarketresearch.com